{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["96(8)"],"submitter":["Rosner A"],"pubmed_abstract":["BriLife<sup>®</sup>, a vector-based vaccine that utilizes the recombinant vesicular stomatitis virus (VSV) platform to express and present the spike antigen of SARS-CoV-2, is undergoing testing in a phase 2 clinical trial in Israel. A nonclinical repeated-dose (GLP) toxicity study in New Zealand white rabbits was performed to evaluate the potential toxicity, local tolerance, immunogenicity and biodistribution of the vaccine. rVSV-ΔG-SARS-CoV-2-S (or vehicle) was administered intramuscularly to two groups of animals (10<sup>6</sup>, 10<sup>7</sup> PFU/animal, n = 10/sex/group) on three occasions, at 2-week intervals, followed by a 3-week recovery period. Systemic clinical signs, local reactions, body weight, body temperature, food consumption, ophthalmology, urinalysis, clinical pathology, "],"journal":["Archives of toxicology"],"pagination":["2329-2339"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9110212"],"repository":["biostudies-literature"],"pubmed_title":["rVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits."],"pmcid":["PMC9110212"],"pubmed_authors":["Yahalom-Ronen Y","Marcus H","Politi B","Madar-Balakirski N","Madar-Shapiro L","Achdout H","Tamir H","Stein D","Kronfeld N","Weiss S","Yitzhaki S","Vitner E","Avraham R","Mechaly A","Rosner A","Cherry L","Fatelevich E","Beth-Din A","Melamed S","Paran N","Levy H","Israely T","Fisher M","Nyska A","Steiner M"],"additional_accession":[]},"is_claimable":false,"name":"rVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits.","description":"BriLife<sup>®</sup>, a vector-based vaccine that utilizes the recombinant vesicular stomatitis virus (VSV) platform to express and present the spike antigen of SARS-CoV-2, is undergoing testing in a phase 2 clinical trial in Israel. A nonclinical repeated-dose (GLP) toxicity study in New Zealand white rabbits was performed to evaluate the potential toxicity, local tolerance, immunogenicity and biodistribution of the vaccine. rVSV-ΔG-SARS-CoV-2-S (or vehicle) was administered intramuscularly to two groups of animals (10<sup>6</sup>, 10<sup>7</sup> PFU/animal, n = 10/sex/group) on three occasions, at 2-week intervals, followed by a 3-week recovery period. Systemic clinical signs, local reactions, body weight, body temperature, food consumption, ophthalmology, urinalysis, clinical pathology, ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-31T07:10:18.492Z","creation":"2025-02-19T05:04:53.496Z"},"accession":"S-EPMC9110212","cross_references":{"pubmed":["35577986"],"doi":["10.1007/s00204-022-03302-5"]}}